This is a Phase III, randomized, open-label multicentre study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with ER-positive HER2-negative advanced breast cancer who have developed resistance to adjuvant endocrine therapy.
New Zealand trial sites are Palmerston North (now recruiting), another North Island site and potentially a South Island site as well.
Read more about this trial here.
4 July 2024
